Passage Bio

We announced our Q4 and full year 2025 financial results and highlighted meaningful progress as we advance our upliFT-D clinical trial in frontotemporal dementia (FTD) and our differentiated preclinical Huntington’s disease program: loom.ly/bAzuoJk

Passage Bio will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference and TD Cowen 46th Annual Health Care Conference, where we will present updates on our progress advancing genetic medicines for neurodegenerative diseases: bit.ly/4rsc3qs

Our team is heading to San Francisco for the 44th Annual @JPMorgan Healthcare Conference! We’re excited to highlight the meaningful progress we’re making to advance our gene therapy programs for neurodegenerative diseases. #JPM26 #FrontotemporalDementia #HuntingtonsDisease

Tomorrow, @AFTDHope will host a webinar highlighting the significant research milestones achieved in FTD this year. Register here to participate in the discussion: bit.ly/4rfNmOq #FrontotemporalDementia

Passage Bio is proud to sponsor the @AFTDHope webinar exploring FTD research and the path towards developing effective treatments. We’re committed to supporting initiatives that drive progress in neurodegenerative disease research. bit.ly/4rfNmOq #FrontotemporalDementia

We announced our Q3 2025 financial results and highlighted meaningful progress as we advance our upliFT-D clinical trial evaluating our investigational therapy in frontotemporal dementia. Read the full update: loom.ly/M5lcLWc

#Investors: We are excited to participate in the Guggenheim 2nd Annual Healthcare Innovation Conference and look forward to connecting and sharing our progress in advancing genetic medicines for neurodegenerative diseases. Learn more: loom.ly/rJH4zRk #InvestorRelations

At the 32nd Annual @ESGCT Congress, our Chief Scientific Officer shared the latest data from our frontotemporal dementia candidate program, sharing insights on advancing gene therapy for neurodegenerative diseases. View our poster presentation here: loom.ly/lUSLg4I #ESGCT

We’re heading to New York for @ChardanCM's 9th Annual Genetic Medicines Conference! Passage Bio will take part in the panel, “Gene Therapy for Neurodegenerative Diseases – Are We There Yet?” Look for us there to learn about our latest progress: loom.ly/SWLVBcQ

Passage Bio is at the 2025 FTD Research Roundtable, working with peers and experts to pave the way for more effective clinical trials and better outcomes for families affected by FTD. Learn more: loom.ly/yfqHYOE #FTD #GeneTherapy #ClinicalResearch #MedEd

ICYMI: Passage Bio CEO, Will Chou, M.D., presented at the @HCWCO Annual Global Investment Conference! He shared our latest advances in genetic medicines for neurodegenerative diseases. Watch the full webcast: loom.ly/EW8dY6w #GeneTherapy #HCWainwright

Passage Bio is attending the @HCWCO 27th Annual Global Investment Conference in NYC where we will share updates on our work in genetic medicines for neurodegenerative diseases. Look for us there! loom.ly/Q31OSxk #HCWainwright #GeneTherapy #InvestorRelations

Our CEO, Will Chou, MD, joins @_CellandGene: The Podcast to discuss the potential of gene therapy in frontotemporal dementia (FTD) and share data from our clinical program presented at #AAIC2025. Listen here: bit.ly/4mFCZQu #GeneTherapy #FTD #Neurodegeneration

Today, we shared our Q2 2025 #financialresults along with important #business updates. Check out our recent progress with the upliFT-D clinical trial and what’s ahead here: loom.ly/N0X7rwg $PASG

Our team just wrapped #AAIC2025! Thank you to everyone who stopped by our poster to learn more about our gene therapy program. #GeneTherapy #NeurodegenerativeDiseases #MedEd

We’re presenting interim data from our Phase 1/2 upliFT-D trial for FTD with GRN mutations at #AAIC2025 — the largest global dementia research conference. Excited to connect and accelerate progress with the community. #GeneticMedicines #ClinicalTrials #MedEd

From all of us at Passage Bio, have a safe and relaxing Independence Day! 🇺🇸 #FourthOfJuly

We’re deeply saddened by the passing of our colleague and friend, Chip Cale, Passage Bio’s General Counsel. Chip’s authenticity, spirit, and dedication left a lasting impact on all who knew him. Our thoughts are with his family and loved ones. loom.ly/MHsVGDk

#NEWS: Today we reported updated interim data from the ongoing Phase 1/2 upliFT-D #clinicaltrial evaluating our potential treatment for frontotemporal #dementia (#FTD) with granulin (GRN) mutations. Read about the data and program updates here: bit.ly/4k0e6xm #meded

We observe #Juneteenth as a company holiday giving our team time to reflect, learn, and support their communities. At Passage Bio, inclusion, equity, and respect are core to who we are. Today and every day, we stand for justice.